세계의 전임상 CRO 시장 보고서(2025년)
Preclinical CRO Global Market Report 2025
상품코드 : 1824307
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

전임상 CRO 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 9.5%를 나타내 89억 9,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 맞춤형 의료 증가, 희소질환 및 희소질환 치료제에 대한 주목, 바이오의약품에서의 아웃소싱 증가, 바이오마커 연구의 중시, 실세계에서의 근거생성 수요 등에 기인한다고 생각됩니다. 예측 기간의 주요 동향은 인공지능(AI)의 통합, 종양학 연구의 확대, 오믹스 기술의 진보, 고급 in vitro 및 in vivo 모델, 트랜스레이셔널 리서치를 위한 공동 연구 등을 포함합니다.

향후 5년간의 성장률 9.5%라고 하는 예측은 전회의 예측으로부터 0.2%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 인상은 인도와 영국에 위탁하고 있는 독성시험과 약물동태시험의 비용을 밀어올려 시험예산을 악화시키고 규제당국에 신청을 지연시킴으로써 미국의 생명공학기업에 부담을 줄 가능성이 높습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.

전임상시험에 대한 수요 증가는 앞으로 전임상 CRO 시장 확대를 촉진할 것으로 예측됩니다. 전임상시험에는 인간 자원봉사자가 피험자로 참여하기 전에 의약품 및 치료법에 대해 수행되는 연구가 포함됩니다. 이러한 조사는 혁신적인 의료기기, 처방약, 진단제 등을 대상으로 하는 경우가 많으며, 주로 퍼스트 인 인간 연구를 위한 안전한 초기 투여량을 결정하고 제품의 잠재적인 독성을 평가하는 것을 목적으로 하고 있습니다. 전임상시험은 의약품 개발에 필수적이며, 그중요성은 신약의 안전성과 효능에 대한 주목이 높아짐에 따라 높아지고 있습니다. 예를 들어, 2024년 2월 미국에 본사를 두고 의료 기술 및 임상 연구 분야에 서비스를 제공하는 IQVIA는 2023년에 임상 개발의 생산성이 향상되었으며 총 69개의 신규 활성 물질(NAS)이 세계에서 상시되었다고 보고했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Preclinical Contract Research Organizations (CROs) play a crucial role as indispensable support entities, providing essential expertise in research and development to guide drug candidates through the animal testing phase and advance them toward the clinical stage. Their significance lies in aiding medical product producers in demonstrating the safety and efficacy of their products in animals that closely mimic human anatomy, adhering to FDA standards. This process is a prerequisite before initiating clinical trials or human applications.

The services offered by preclinical CROs cover a wide spectrum, including bioanalysis and DMPK studies, toxicology testing, compound management, chemistry, safety pharmacology, and more. A notable advancement in this domain is the adoption of patient-derived organoids (PDOs), which are small three-dimensional cell cultures created from a patient's cancer cells. Substantial investments and experimental validation efforts have been dedicated to PDOs, presenting promising therapeutic alternatives for diagnosing complex diseases. The repertoire of preclinical CRO services encompasses various models, such as the patient-derived organoid (PDO) model and patient-derived xenograft model, applicable to both small and large animal models. These model systems, spanning In Vivo and In Vitro approaches, find applications among biopharmaceutical companies, government and academic institutes, medical device companies, and other stakeholders.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The preclinical CRO market research report is one of a series of new reports from The Business Research Company that provides preclinical CRO market statistics, including preclinical CRO industry global market size, regional shares, competitors with an preclinical CRO market share, detailed preclinical CRO market segments, market trends and opportunities, and any further data you may need to thrive in the preclinical CRO industry. This preclinical CRO market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The preclinical cro market size has grown strongly in recent years. It will grow from $5.7 billion in 2024 to $6.25 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to demand for faster drug development, cost containment strategies, focus on core competencies, regulatory compliance requirements, globalization of clinical trials.

The preclinical cro market size is expected to see strong growth in the next few years. It will grow to $8.99 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to rise in personalized medicine, focus on rare diseases and orphan drugs, increased outsourcing in biopharmaceuticals, emphasis on biomarker research, demand for real-world evidence generation. Major trends in the forecast period include integration of artificial intelligence (AI), expansion of oncology research, advances in omics technologies, advanced in vitro and in vivo models, collaboration for translational research.

The forecast of 9.5% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. biotech firms by driving up the cost of outsourced toxicology studies and pharmacokinetic testing sourced from India and the UK, exacerbating trial budgets and delaying regulatory submissions. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing demand for preclinical trials is projected to drive the expansion of the preclinical contract research organization (CRO) market in the future. Preclinical trials involve studies conducted on medicines or treatments for a condition before human volunteers are involved as test subjects. These studies often encompass innovative medical devices, prescription medications, and diagnostics, primarily aiming to determine a safe initial dose for first-in-human research and assess any potential toxicity of the product. Preclinical trials are essential to drug development, and their significance is heightened by the increasing focus on the safety and efficacy of new drugs. For instance, in February 2024, IQVIA, a U.S.-based company serving the healthcare technology and clinical research sectors, reported that clinical development productivity improved in 2023, with a total of 69 novel active substances (NASs) launched globally, which is six more than the previous year, including 24 first-in-class launches in the U.S. Consequently, the rising demand for preclinical trials is fueling the growth of the preclinical CRO market.

The increasing need for outsourcing services is poised to be a driving force behind the growth of the preclinical CRO market in the coming years. Outsourcing services involve contracting with third-party vendors to manage specific business tasks or operations. The complexity of preclinical research is on the rise, requiring specialized skills and expertise not always available in-house for pharmaceutical and biotechnology companies. Outsourcing to preclinical CROs allows companies to access the necessary expertise without the burden of building internal capabilities, enabling them to focus on core business activities while ensuring the completion of preclinical research. In April 2023, a survey by BioPlan Associates Inc. revealed that 84.6% of biomanufacturers are outsourcing analytical testing, and 74.5% are outsourcing toxicity testing in 2023. This underscores the increasing reliance on outsourcing services, contributing to the upward trajectory of the preclinical CRO market.

Technological advancements are a prominent trend gaining momentum in the preclinical Contract Research Organization (CRO) market, with significant companies in the sector adopting innovative technologies to strengthen their market positions. In February 2023, BenchSci, a Canada-based AI solutions company specializing in preclinical Research and Development (R&D), introduced ASCEND, an end-to-end Software as a Service (SaaS) platform for preclinical drug discovery. Leveraging artificial intelligence, ASCEND accelerates the preclinical phase of drug development pipelines by deriving biological insights into the foundational aspects of diseases. BenchSci's machine learning technology is employed to extract experimental data from both internal and external sources, enabling a comparison of results using curated ontology datasets. This approach facilitates the creation of evidence-based maps illustrating the biological processes underlying various diseases.

Key players in the preclinical CRO landscape are actively engaging in collaborations and partnerships to enhance their service offerings. Strategic partnerships, characterized by structured affiliations through business agreements or contracts, are a focal point in this context. In February 2022, IonsGate Preclinical Services Inc., a Canada-based CRO specializing in preclinical research services, announced a partnership with Insilicotrials Technologies Srl, an Italy-based provider of specialized consultancy for clinical trial solutions. This collaborative effort aims to leverage innovative technologies to expedite drug discovery processes, enabling more comprehensive preclinical testing capable of identifying potential safety risks at earlier stages of development.

In June 2022, Asahi Kasei Medical Co. Ltd., a Japan-based chemical company, successfully completed the acquisition of Bionova Scientific, LLC, in an undisclosed transaction. This strategic acquisition enhances Asahi Kasei Medical's bioprocess business by integrating a biopharmaceutical Contract Development and Manufacturing Organization (CDMO). The move broadens their customer base, particularly among those engaged in the development of cutting-edge next-generation biopharmaceuticals. Bionova Scientific LLC, a US-based company, specializes in offering contract process development services and Good Manufacturing Practice (GMP)-compliant contract manufacturing services for biopharmaceutical firms.

Major companies operating in the preclinical CRO market include Eurofins Scientific SE, PRA Health Sciences Inc., Wuxi AppTec Co. Ltd., Medpace Holdings Inc., Charles River Laboratories International Inc., Laboratory Corporation of America Holdings, SGA SA, Intertek Group plc, Crown Bioscience International, Cynbiose, AmplifyBio LLC, Vivotecnia SL, Simavita Ltd., BioEmission Technology Solutions, Altasciences Company Inc., Global Center For Medical Innovation, Pharmaceutical Product Development LLC, Parexel International Corporation, Envigo RMS Holding Corporation, Veeda Clinical Research Ltd., ICON plc, Kunming Biomed International Ltd., PharmaLegacy Laboratories, NorthEast BioAnalytical Laboratories LLC, MDS Pharma Services, MPI Research, Toxikon Corporation, BioReliance Corporation, Covance Inc., Syngene International Limited

North America was the largest region in the preclinical CRO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global preclinical CRO market during the forecast period. The regions covered in the preclinical cro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the preclinical cro market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The preclinical CRO market includes revenues earned by entities through project management, information gathering, medical evaluations, maximum dose research, adherence to regulations, efficacy and safety reporting, and quality analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Preclinical CRO Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on preclinical cro market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for preclinical cro ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The preclinical cro market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Preclinical CRO Market Characteristics

3. Preclinical CRO Market Trends And Strategies

4. Preclinical CRO Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Preclinical CRO Growth Analysis And Strategic Analysis Framework

6. Preclinical CRO Market Segmentation

7. Preclinical CRO Market Regional And Country Analysis

8. Asia-Pacific Preclinical CRO Market

9. China Preclinical CRO Market

10. India Preclinical CRO Market

11. Japan Preclinical CRO Market

12. Australia Preclinical CRO Market

13. Indonesia Preclinical CRO Market

14. South Korea Preclinical CRO Market

15. Western Europe Preclinical CRO Market

16. UK Preclinical CRO Market

17. Germany Preclinical CRO Market

18. France Preclinical CRO Market

19. Italy Preclinical CRO Market

20. Spain Preclinical CRO Market

21. Eastern Europe Preclinical CRO Market

22. Russia Preclinical CRO Market

23. North America Preclinical CRO Market

24. USA Preclinical CRO Market

25. Canada Preclinical CRO Market

26. South America Preclinical CRO Market

27. Brazil Preclinical CRO Market

28. Middle East Preclinical CRO Market

29. Africa Preclinical CRO Market

30. Preclinical CRO Market Competitive Landscape And Company Profiles

31. Preclinical CRO Market Other Major And Innovative Companies

32. Global Preclinical CRO Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Preclinical CRO Market

34. Recent Developments In The Preclinical CRO Market

35. Preclinical CRO Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기